Affordable Access

Future role of radiotherapy as a component of treatment in biliopancreatic cancers.

Authors
  • Gunderson, L L
  • Haddock, M G
  • Burch, P
  • Nagorney, D
  • Foo, M L
  • Todoroki, T
Type
Published Article
Journal
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
Publication Date
Jan 01, 1999
Volume
10 Suppl 4
Pages
291–295
Identifiers
PMID: 10436843
Source
Medline
License
Unknown

Abstract

For resected and unresectable pancreas cancers, data will be summarized from both adjuvant and locally unresectable pancreas cancer series (EBRT +/- IOERT) to demonstrate the justification of continuing to utilize chemo-irradiation as a component of treatment. The resultant improvements in local control with combined modality treatment, however, achieve only minimal improvements in survival in view of the high incidence of abdominal relapse (liver and peritoneal). Further improvement in survival may necessitate regional approaches for chemotherapy or may await advances in gene therapy. For locally unresectable and resected but residual bile duct malignancies, chemoirradiation appears to enhance tumor control and survival. Dose intensification of both modalities may be useful in improving disease control and survival. After chemoirradiation, the addition of liver transplant, in carefully selected patients who are unresectable with standard resection, may further enhance disease control and survival over what would be expected with either approach in isolation.

Report this publication

Statistics

Seen <100 times